Literature DB >> 14752330

Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a model of immune dysregulation.

Troy R Torgerson1, Hans D Ochs.   

Abstract

PURPOSE OF REVIEW: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome is a fatal syndrome of overwhelming autoimmunity. Recent identification of FOXP3 as the causative gene and realization that this same gene defect occurs in the mutant mouse Scurfy has yielded new insights and hopes of unraveling the mechanism of autoimmunity in this and possibly other diseases. In this review, we describe the clinical features of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome/Scurfy and compare this phenotype with similar syndromes caused by other single gene mutations. We examine therapeutic options to treat the syndrome, study its immunologic basis, and investigate the structure and function of the FOXP3 protein. RECENT
FINDINGS: The Scurfy mutant mouse has a characteristic phenotype that causes death by approximately 3 weeks of age. It is known that the effector cells in the Scurfy mouse are CD4+ T cells and that a population of normal T cells can control the overwhelming autoimmunity that they induce. Recent data have demonstrated that this process requires antigenic stimulation and that the degree to which the immune system responds is inversely proportional to the level of FOXP3 protein (Forkhead box P3) expression in peripheral T cells. Suppression of immune activation by FOXP3 may occur due to its ability to bind to DNA through a putative forkhead DNA-binding motif and to repress transcriptional activation from certain promoters in T cells.
SUMMARY: Because of the dramatic phenotype and rapidity of onset, immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome and Scurfy provide a powerful model in which to study mechanisms of T cell regulation. A more complete understanding of this syndrome will provide important insights into mechanisms of immune suppression, tolerance, and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14752330     DOI: 10.1097/00130832-200212000-00002

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  15 in total

Review 1.  The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer.

Authors:  Frances Mercer; Derya Unutmaz
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

2.  Exome sequencing identifies a novel FOXP3 mutation in a 2-generation family with inflammatory bowel disease.

Authors:  David T Okou; Kajari Mondal; William A Faubion; Lisa J Kobrynski; Lee A Denson; Jennifer G Mulle; Dhanya Ramachandran; Yuning Xiong; Phyllis Svingen; Viren Patel; Promita Bose; Jon P Waters; Sampath Prahalad; David J Cutler; Michael E Zwick; Subra Kugathasan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-05       Impact factor: 2.839

Review 3.  FOXP3 and the regulation of Treg/Th17 differentiation.

Authors:  Steven F Ziegler; Jane H Buckner
Journal:  Microbes Infect       Date:  2009-04-14       Impact factor: 2.700

4.  FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.

Authors:  Morna J Dorsey; A Petrovic; M R Morrow; L J Dishaw; J W Sleasman
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

5.  Engineered regulatory T cells coexpressing MHC class II:peptide complexes are efficient inhibitors of autoimmune T cell function and prevent the development of autoimmune arthritis.

Authors:  Zhaohui Qian; Kary A Latham; Karen B Whittington; David C Miller; David D Brand; Edward F Rosloniec
Journal:  J Immunol       Date:  2013-04-29       Impact factor: 5.422

6.  Foxp3 and Treg cells in HIV-1 infection and immuno-pathogenesis.

Authors:  Derek Holmes; Qi Jiang; Liguo Zhang; Lishan Su
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

7.  FoxP3 enhances HIV-1 gene expression by modulating NFkappaB occupancy at the long terminal repeat in human T cells.

Authors:  Derek Holmes; Geoffry Knudsen; Stephanie Mackey-Cushman; Lishan Su
Journal:  J Biol Chem       Date:  2007-04-06       Impact factor: 5.157

Review 8.  The NLR network and the immunological disease continuum of adaptive and innate immune-mediated inflammation against self.

Authors:  Dennis McGonagle; Sinisa Savic; Michael F McDermott
Journal:  Semin Immunopathol       Date:  2007-09-06       Impact factor: 11.759

9.  The genetic basis of severe combined immunodeficiency and its variants.

Authors:  Diana Tasher; Ilan Dalal
Journal:  Appl Clin Genet       Date:  2012-08-07

Review 10.  Approach to the patient with recurrent infections.

Authors:  Mark Ballow
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 10.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.